drugset / Trial / NCT02120781

Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia

NCT02120781 ↗

Phase 2 Completed 21 enrolled Castle Creek Biosciences, LLC.
RandomizedParallel-groupTriple-blindTreatment

Summary

The objectives of this study are to assess the safety of azficel-T treatment for dysphonia related to vocal fold function and to evaluate the efficacy of azficel-T for the treatment of dysphonia related to vocal fold function.

Timeline

Start
2014-03
Primary completion
2016-04
Completion
2016-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Azficel-T (autologous fibroblasts) Cell therapy 1 ml Other